Minprostin (Dinoprostone)
Prostaglandin E2 vaginal gel for labor induction
Minprostin is a prescription vaginal gel containing dinoprostone (prostaglandin E2) used exclusively in hospital settings to induce labor at or near full-term pregnancy. It works by softening and ripening the cervix while stimulating uterine contractions. Minprostin is administered by trained healthcare professionals with continuous fetal and maternal monitoring.
Quick Facts
Key Takeaways
- Minprostin contains dinoprostone (prostaglandin E2) and is used exclusively for labor induction in hospital settings with trained staff and monitoring equipment.
- The medication works by softening and ripening the cervix while initiating uterine contractions, helping to prepare the body for childbirth.
- An initial dose of 1 mg is administered vaginally; a repeat dose of 1 mg or 2 mg may follow after 6 hours if needed.
- Oxytocin must not be given within 6 hours after the last Minprostin dose to avoid dangerous uterine hyperstimulation.
- Women with previous cesarean section, placenta previa, or certain other obstetric conditions must not receive Minprostin.
What Is Minprostin and What Is It Used For?
Minprostin contains the active substance dinoprostone, which belongs to a group of naturally occurring hormones called prostaglandins. Prostaglandin E2 (PGE2) plays a central role in the natural process of labor initiation, and dinoprostone is a synthetic form of this hormone. When applied vaginally, it mimics the body's own prostaglandin activity to promote cervical ripening and the onset of labor.
The cervix normally undergoes a gradual softening and thinning process (known as effacement) in the final weeks of pregnancy, preparing for dilation during labor. In some cases, this process does not occur naturally or needs to be accelerated for medical reasons. Minprostin facilitates this by acting directly on the cervical tissue, causing it to soften, thin, and begin to dilate, while simultaneously stimulating rhythmic contractions of the uterine smooth muscle.
Labor induction with Minprostin is indicated when continuing the pregnancy poses greater risks than delivery. Common medical reasons for induction include post-term pregnancy (exceeding 41–42 weeks of gestation), pre-eclampsia or gestational hypertension, gestational diabetes with complications, prelabor rupture of membranes without spontaneous onset of contractions, intrauterine growth restriction, and oligohydramnios (reduced amniotic fluid). The decision to induce labor is always made by an obstetrician after careful assessment of both maternal and fetal well-being.
Dinoprostone is available under several brand names worldwide, including Minprostin, Cervidil, Propess, and Prostin E2. While the formulations may differ (gel, vaginal insert, or tablet), they all contain dinoprostone as the active ingredient and share the same mechanism of action. Minprostin specifically refers to the vaginal gel formulation supplied in a pre-filled syringe for accurate dosing.
It is important to understand that Minprostin is not a medication for home use. It must only be administered in a hospital or birthing center by trained healthcare professionals (obstetricians or midwives) who have access to appropriate monitoring equipment for both the mother and the baby, including cardiotocography (CTG) for continuous fetal heart rate monitoring.
Dinoprostone binds to EP2 and EP4 prostaglandin receptors in cervical tissue, triggering a cascade of enzymatic activity that breaks down collagen fibers in the cervix. This process, known as cervical ripening, transforms the cervix from a firm, closed structure into a soft, compliant one that can dilate during labor. Simultaneously, dinoprostone acts on EP1 and EP3 receptors in the myometrium (uterine muscle), stimulating calcium release and rhythmic smooth muscle contractions.
What Should You Know Before Receiving Minprostin?
Contraindications
There are several situations in which Minprostin must not be used. These contraindications are absolute, meaning the drug should never be administered under these circumstances regardless of other considerations. Your obstetric team will perform a thorough assessment before proceeding with induction to ensure that none of these conditions are present.
- You are allergic to prostaglandins, dinoprostone, or any other ingredient in this medicine (colloidal anhydrous silica, glyceryl triacetate)
- The placenta is covering the cervical opening (placenta previa)
- The size of the baby's head may cause problems during delivery (cephalopelvic disproportion)
- The baby's position in the uterus does not allow vaginal delivery (e.g., transverse lie)
- You have completed more than 6 full-term pregnancies (grand multiparity)
- You have undergone previous surgery on the uterus, including cesarean section
- The baby shows signs of distress (abnormal fetal heart rate pattern)
- There is an indication for cesarean delivery
- You have had unexplained vaginal bleeding during the current pregnancy
The restriction regarding previous uterine surgery, including cesarean section, is of particular clinical importance. A scarred uterus carries an increased risk of uterine rupture when exposed to prostaglandins, which can be a life-threatening emergency for both the mother and the baby. According to guidelines from the American College of Obstetricians and Gynecologists (ACOG) and the National Institute for Health and Care Excellence (NICE), prostaglandin-based cervical ripening agents should generally be avoided in women with a prior uterine scar.
Grand multiparity (having had more than six full-term deliveries) is a contraindication because the uterine wall may be thinner and more susceptible to rupture from the stimulating effects of prostaglandins. Similarly, cephalopelvic disproportion means that vaginal delivery is not safely possible regardless of the success of cervical ripening, making induction with Minprostin inappropriate.
Warnings and Precautions
Even in the absence of absolute contraindications, there are several conditions that require special caution and enhanced monitoring. Speak with your doctor or midwife before receiving Minprostin if any of the following apply to you:
- Ruptured membranes: If your waters have already broken, the risk-benefit ratio of prostaglandin administration changes, and alternative induction methods may be preferred to reduce the risk of ascending infection.
- Previous complicated deliveries: A history of prolonged labor, precipitous labor, uterine hyperstimulation, or traumatic delivery may increase the risk of complications with prostaglandin induction.
- Multiple pregnancy: Carrying twins or more increases the complexity of induction and requires enhanced monitoring due to the increased uterine distension.
- Glaucoma or elevated intraocular pressure: Prostaglandins can affect intraocular pressure, and patients with these conditions require careful ophthalmologic consideration.
- Epidural anesthesia: If you are receiving or planning epidural anesthesia, inform your healthcare team, as the combination requires coordinated management to ensure hyperstimulation can be detected.
- Asthma: Current or previous asthma may be exacerbated by prostaglandins, which can cause bronchoconstriction in susceptible individuals. Dinoprostone should be used with caution in these patients.
- Cardiovascular disease: Heart conditions may be worsened by the hemodynamic effects of prostaglandins and the physiological stress of induced labor.
- Impaired kidney or liver function: Reduced organ function may affect the metabolism and clearance of dinoprostone, potentially leading to prolonged effects.
- Age 35 or older with pregnancy complications: Women aged 35 and older who also have conditions such as gestational diabetes, hypertension, hypothyroidism, or pregnancies exceeding 41 weeks are at increased risk of developing disseminated intravascular coagulation (DIC), a rare but serious condition affecting blood clotting.
Pregnancy and Breastfeeding
Minprostin is specifically designed for use during pregnancy, but only at or near full term for the purpose of inducing labor. It should not be used during any other phase of pregnancy. The use of dinoprostone in early pregnancy or for non-obstetric indications is outside the scope of Minprostin's approved use and could result in serious harm to the developing fetus.
Regarding breastfeeding, Minprostin is administered as a single-use or limited-dose treatment during labor, and dinoprostone is rapidly metabolized in the body with a half-life of less than 5 minutes in the bloodstream. There is no clinical concern regarding breastfeeding after delivery following Minprostin use. Prostaglandin E2 is a naturally occurring substance in the body and does not accumulate in breast milk in clinically significant amounts.
The use of Minprostin during labor does not affect the ability to initiate breastfeeding or the quality of breast milk. Women who receive Minprostin for labor induction can breastfeed their newborn immediately after delivery, following the same guidelines as any other delivery method.
How Does Minprostin Interact with Other Drugs?
Because Minprostin is used exclusively in a controlled hospital environment, drug interactions are typically managed by the healthcare team. However, it is essential to inform your doctor about all medications you are taking, including over-the-counter medicines, herbal supplements, and vitamins. This allows your care team to plan the safest induction strategy for your individual circumstances.
Major Interactions
| Drug | Interaction | Clinical Significance |
|---|---|---|
| Oxytocin (Syntocinon, Pitocin) | Synergistic uterotonic effect leading to excessive uterine stimulation | Must wait at least 6 hours after last Minprostin dose before starting oxytocin. Risk of uterine hyperstimulation with excessively strong, frequent, or prolonged contractions. |
| Other prostaglandins (misoprostol, carboprost) | Additive prostaglandin effects on uterine muscle | Concurrent use significantly increases the risk of uterine hyperstimulation, tachysystole, and potential uterine rupture. |
The interaction between Minprostin and oxytocin is the most clinically important consideration. Both agents promote uterine contractions through different but complementary mechanisms. Dinoprostone works primarily through prostaglandin receptors, while oxytocin acts through its own specific receptors on the myometrium. When used in sequence with adequate spacing (minimum 6 hours), they can be an effective combined strategy for labor induction. However, overlapping their effects leads to potentially dangerous uterine hyperstimulation.
Considerations with Other Medications
Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and aspirin can theoretically counteract the effects of prostaglandins because NSAIDs inhibit prostaglandin synthesis. While this is primarily a pharmacological consideration, it is worth noting that NSAIDs are generally avoided during the third trimester of pregnancy for other reasons, including the risk of premature closure of the ductus arteriosus and reduced amniotic fluid volume.
Epidural anesthesia does not directly interact with dinoprostone pharmacologically. However, the combination requires coordinated clinical management because epidural anesthesia can mask the pain of uterine hyperstimulation, potentially delaying recognition of this serious complication. Close monitoring of uterine activity via CTG is therefore essential when both are used concurrently.
Tocolytic agents (medications used to suppress premature labor contractions, such as terbutaline or atosiban) may reduce the effectiveness of dinoprostone if given concurrently. If tocolysis is needed to manage hyperstimulation after Minprostin administration, this represents an emergency intervention rather than a planned drug combination. Beta-2 agonists like terbutaline can rapidly relax the uterine muscle and are the first-line treatment for acute hyperstimulation.
Corticosteroids, which may be administered before induction to promote fetal lung maturity in certain situations, do not interact with dinoprostone. The two can be safely used in the same clinical pathway without dose adjustments or timing concerns.
What Is the Correct Dosage of Minprostin?
Minprostin is not self-administered. It is always given by trained healthcare professionals — typically an obstetrician or experienced midwife — in a hospital or birth center equipped with continuous fetal and maternal monitoring capabilities. The dosing protocol follows established obstetric guidelines and is individualized based on cervical status (typically assessed using the Bishop score) and clinical response.
Standard Dosing Protocol
- Initial dose: 1 mg dinoprostone gel placed in the posterior vaginal fornix (the area near the cervix)
- Repeat dose (if needed): 1 mg or 2 mg after a minimum interval of 6 hours
- Maximum recommended doses: The total dose and number of applications are determined by the attending physician based on individual response and cervical progress
- Administration method: Pre-filled syringe containing 2.5 ml gel, delivered directly to the posterior fornix by a trained clinician
| Scenario | Dose | Timing | Notes |
|---|---|---|---|
| Initial application | 1 mg (2.5 ml gel) | Once cervical assessment is complete | CTG monitoring 30 min before and ≥1 hour after |
| Repeat dose (favorable response) | 1 mg (2.5 ml gel) | After 6 hours minimum | Only if labor not yet established and cervix improving |
| Repeat dose (insufficient response) | 2 mg (2.5 ml gel) | After 6 hours minimum | Higher dose if cervical response was minimal |
Monitoring During Treatment
Fetal heart activity and uterine contractions are monitored using CTG (cardiotocography) for at least 30 minutes before administration and continuously for at least 1 hour after each dose. This monitoring is essential to detect early signs of fetal distress or uterine hyperstimulation. The frequency and duration of contractions, fetal heart rate patterns, and maternal vital signs are all closely observed throughout the induction process.
The Bishop score, a clinical assessment of cervical readiness based on dilation, effacement, station, consistency, and position, is evaluated before each dose to determine the need for further treatment. A Bishop score of 6 or higher typically indicates that the cervix is favorable for labor induction and that oxytocin may be used directly rather than additional prostaglandin doses.
If regular contractions develop and labor progresses satisfactorily, no additional doses are needed. If labor does not establish after repeated doses, the physician will reassess the clinical situation and may consider alternative approaches such as mechanical cervical ripening (balloon catheter), amniotomy (artificial rupture of membranes), or cesarean delivery.
Overdose
Because Minprostin is administered by healthcare professionals in a controlled setting, overdose is extremely unlikely. However, if excessive doses are given, the primary concern is uterine hyperstimulation — contractions that are too strong (hypertonic), too frequent (tachysystole, defined as more than 5 contractions in 10 minutes), or too prolonged (lasting more than 2 minutes without adequate relaxation).
Signs of hyperstimulation include continuous uterine contraction without relaxation, fetal heart rate abnormalities (persistent bradycardia, late decelerations, or loss of variability), and severe abdominal pain. These signs require immediate clinical intervention.
Management of hyperstimulation includes immediate cessation of any uterotonic medication, repositioning the patient to the left lateral position to improve uterine blood flow, administration of intravenous fluids, possible use of tocolytic agents (such as terbutaline 250 mcg subcutaneously) to relax the uterus, and emergency cesarean delivery if fetal distress persists despite conservative measures. These interventions are performed by the obstetric team as part of standard emergency protocols available in all labor wards.
What Are the Side Effects of Minprostin?
Like all medicines, Minprostin can cause side effects, although not everyone experiences them. The side effects are categorized by how frequently they occur, based on clinical trial data and post-marketing surveillance. Most side effects are related to the pharmacological action of prostaglandins on smooth muscle tissue and are managed by the clinical team during the induction process.
Common
May affect up to 1 in 10 patients
- Abdominal pain (related to uterine contractions)
- Uterine hyperstimulation (contractions that are too strong, too frequent, or too prolonged)
Uncommon
May affect up to 1 in 100 patients
- Nausea
- Vomiting
- Diarrhea
- Sensation of warmth in the vagina
Rare
May affect up to 1 in 1,000 patients
- Fever
- Back pain
- Hypersensitivity reactions
- Fetal heart rate changes indicating fetal distress (isolated cases of fetal death have been reported in association with dinoprostone treatment)
- Uterine rupture
- Disseminated intravascular coagulation (DIC) — a rare condition affecting blood clotting
Frequency Not Known
Cannot be estimated from available data
- Severe hypersensitivity reactions (anaphylactic reactions, anaphylactic shock, anaphylactoid reactions)
- Fetal death, stillbirth, and neonatal death — particularly following serious complications such as uterine rupture
Tell your midwife or doctor right away if you experience any of the following during or after Minprostin administration: continuous severe abdominal pain without relaxation between contractions, sudden sharp pain in your abdomen, vaginal bleeding, dizziness or feeling faint, difficulty breathing, or if your baby seems to be moving much less than normal. The clinical team is trained to recognize and manage these situations promptly.
It is important to understand that uterine hyperstimulation is a recognized complication of all prostaglandin-based induction methods, not just Minprostin. The clinical team is trained to recognize and manage this condition promptly. Continuous CTG monitoring during and after administration allows early detection of both uterine hyperstimulation and fetal distress, enabling rapid intervention when needed. In most cases, hyperstimulation resolves when the uterotonic stimulus is removed, although tocolytic medication may occasionally be required.
The risk of uterine rupture is primarily associated with patients who have a scarred uterus (e.g., from previous cesarean section or myomectomy), which is why prior uterine surgery is listed as a contraindication. In patients with an unscarred uterus, uterine rupture is extremely rare — estimated at fewer than 1 in 10,000 inductions — but remains a possibility that the clinical team is prepared to manage with emergency cesarean delivery.
DIC is a very rare but potentially life-threatening complication that is more likely to occur in older women (35+) with concurrent pregnancy complications such as pre-eclampsia, placental abruption, or prolonged fetal death. It involves widespread activation of the blood clotting cascade, which can paradoxically lead to both thrombosis and hemorrhage simultaneously. The obstetric team monitors for early signs of this condition through regular blood tests in high-risk patients.
The gastrointestinal side effects (nausea, vomiting, diarrhea) are related to the effect of prostaglandins on smooth muscle throughout the body, not just the uterus. These effects are generally mild and self-limiting. The sensation of vaginal warmth is a local effect of the gel and typically resolves shortly after application.
How Should Minprostin Be Stored?
As a hospital-administered medication, storage of Minprostin is managed by the pharmacy and clinical staff. However, the following storage requirements are important for maintaining the integrity and efficacy of the product:
- Temperature: Store in a refrigerator at 2°C–8°C (36°F–46°F). Do not freeze.
- Light protection: Keep in the original packaging to protect from light.
- Child safety: Keep out of the sight and reach of children.
- Expiration: Do not use after the expiration date (EXP) printed on the carton and pre-filled syringe. The expiration date refers to the last day of that month.
- Single use: Each pre-filled syringe is for single use only. Any unused product should be disposed of according to local pharmaceutical waste disposal regulations.
- Environmental disposal: Do not dispose of this medicine via household waste or wastewater. Return unused medicine to a pharmacy or hospital for proper disposal to protect the environment.
The cold-chain storage requirement is critical for Minprostin. Dinoprostone is a biologically active prostaglandin that can degrade if exposed to temperatures outside the recommended range, potentially reducing its efficacy or altering its safety profile. Hospital pharmacies maintain strict cold-chain management protocols from receipt of the product through to administration at the bedside. If there is any doubt about whether the cold chain has been maintained, the product should not be used and should be discarded appropriately.
When Minprostin is removed from the refrigerator for administration, it should be allowed to reach room temperature briefly before use, as application of very cold gel may cause patient discomfort. However, extended exposure to room temperature should be avoided, and any unused syringes should be promptly returned to refrigerated storage.
What Does Minprostin Contain?
Minprostin vaginal gel is a clear, colorless to slightly yellowish gel supplied in a pre-filled single-dose syringe containing 2.5 ml of gel. The formulation is designed for localized vaginal application, ensuring sustained contact with the cervical tissue for optimal drug delivery. The complete composition is as follows:
| Component | Function | Amount |
|---|---|---|
| Dinoprostone (PGE2) | Active ingredient — cervical ripening agent and uterotonic | 1 mg or 2 mg per syringe |
| Colloidal anhydrous silica | Gel-forming agent (thickener) | As required for gel formulation |
| Glyceryl triacetate (triacetin) | Gel base and solvent | Vehicle to 2.5 ml |
The gel formulation is designed to adhere to the cervical and vaginal tissue upon application, allowing sustained local release of dinoprostone at the site of action. This localized delivery approach helps maximize the cervical ripening effect while minimizing systemic absorption and the associated risk of systemic side effects. The gel matrix formed by colloidal silica in triacetin provides a stable vehicle that maintains drug release over several hours.
Minprostin does not contain any preservatives, latex, or common allergens such as gluten or lactose. The pre-filled syringe is made of medical-grade materials and is designed for single vaginal application with a catheter attachment for accurate placement. Patients with known allergies to prostaglandins or either of the excipients (colloidal silica or triacetin) should not receive this product and should inform their healthcare team of any known drug allergies before induction.
The two available strengths (1 mg and 2 mg) contain the same volume of gel (2.5 ml) but differ in the concentration of dinoprostone. This allows the clinician to select the appropriate dose based on the clinical situation without needing to calculate volumes. The 1 mg strength is used for the initial dose, while the 2 mg strength is available for repeat dosing when a stronger cervical ripening effect is needed.
Frequently Asked Questions About Minprostin
Minprostin is a vaginal gel containing dinoprostone (prostaglandin E2) used exclusively in hospitals to induce labor in pregnant women at or near full-term pregnancy. It works by softening and ripening the cervix while stimulating uterine contractions. Common reasons for labor induction include post-term pregnancy, pre-eclampsia, gestational diabetes complications, and premature rupture of membranes without spontaneous labor onset.
Minprostin is administered as a vaginal gel by a trained doctor or midwife in a hospital setting. An initial dose of 1 mg is placed in the posterior vaginal fornix (near the cervix) using a pre-filled syringe. If needed, a second dose of 1 mg or 2 mg may be given after at least 6 hours. Fetal heart rate and uterine contractions are continuously monitored using CTG (cardiotocography) starting 30 minutes before administration and for at least 1 hour afterward.
The time for Minprostin to take effect varies considerably between individuals. Some women may begin to experience contractions within 30 minutes to 1 hour, while others may require several hours for significant cervical changes to occur. Some women may need a repeat dose after 6 hours. In general, the overall induction process from first application to active labor can take anywhere from a few hours to more than 24 hours, depending on the initial cervical status (Bishop score) and individual response.
No. Minprostin is contraindicated in women who have previously had a cesarean section or any other uterine surgery. The presence of a uterine scar significantly increases the risk of uterine rupture during prostaglandin-induced labor, which can be life-threatening for both the mother and baby. Women with a prior cesarean who require labor induction should discuss alternative methods with their obstetrician, such as mechanical cervical ripening with a balloon catheter or planned repeat cesarean delivery.
Oxytocin (brand names Syntocinon, Pitocin) should not be started within 6 hours of the last Minprostin dose because both medications stimulate uterine contractions through different mechanisms. Using them together or too close together can cause uterine hyperstimulation — dangerously strong, frequent, or prolonged contractions that can compromise blood flow to the baby, cause fetal distress, or in severe cases lead to uterine rupture. The 6-hour waiting period allows the effects of dinoprostone to subside before oxytocin augmentation begins.
When used appropriately under proper medical supervision with continuous fetal monitoring, Minprostin is considered safe for both mother and baby. Dinoprostone has been used for decades in obstetric practice and is supported by extensive clinical evidence from systematic reviews and randomized controlled trials. However, as with any labor induction method, there are inherent risks including the possibility of fetal heart rate changes due to uterine hyperstimulation. This is why continuous CTG monitoring is mandatory during and after administration, allowing the clinical team to intervene promptly if any concerns arise.
References
This article is based on the following peer-reviewed sources and international clinical guidelines:
- World Health Organization (WHO). WHO Recommendations: Induction of Labour at or Beyond Term. Geneva: WHO; 2022.
- National Institute for Health and Care Excellence (NICE). Inducing Labour [NG207]. London: NICE; 2021 (updated 2024).
- American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 107: Induction of Labor. Obstet Gynecol. 2009 (reaffirmed 2023).
- Thomas J, Fairclough A, Kavanagh J, Kelly AJ. Vaginal prostaglandin (PGE2 and PGF2a) for induction of labour at term. Cochrane Database Syst Rev. 2014;(6):CD003101. doi:10.1002/14651858.CD003101.pub3
- European Medicines Agency (EMA). Summary of Product Characteristics: Dinoprostone. EMA; 2023.
- Royal College of Obstetricians and Gynaecologists (RCOG). Induction of Labour at Term (Green-top Guideline). London: RCOG; 2023.
- British National Formulary (BNF). Dinoprostone. London: BMJ Group and Pharmaceutical Press; 2024.
- Mozurkewich EL, Chilimigras JL, Berman DR, et al. Methods of induction of labour: a systematic review. BMC Pregnancy Childbirth. 2011;11:84. doi:10.1186/1471-2393-11-84
Editorial Team
This article was written by the iMedic Medical Editorial Team, a group of licensed physicians with expertise in obstetrics, gynecology, and clinical pharmacology. All content follows the GRADE evidence framework and adheres to guidelines from WHO, ACOG, NICE, and RCOG.
Reviewed by the iMedic Medical Review Board, an independent panel of specialists ensuring accuracy, completeness, and adherence to current evidence-based guidelines.
Evidence Level 1A based on systematic reviews and meta-analyses. No commercial funding or pharmaceutical sponsorship. Independent editorial content with full transparency.